<DOC>
	<DOCNO>NCT02322775</DOCNO>
	<brief_summary>The purpose trial confirm safety clinical benefit benralizumab administration asthma patient mild moderate persistent asthma order gain understanding benefit/risk benralizumab across spectrum asthma disease .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Benralizumab Adult Patients With Mild Moderate Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Written inform consent study participation must obtain prior study related procedure perform accord international guideline and/or applicable European Union ( EU ) guideline . Female male age 18 75 year , inclusively , time Visit 1 . Weight ≥40 kg . Evidence asthma document postbronchodilator ( postBD ) reversibility FEV1 ≥ 12 % demonstrate Visit 2 . Documented use 1 follow type asthma therapy time informed consent : Low mediumdose ICS ( ie , 100 500 μg fluticasone dry powder formulation equivalent total daily dose ) without controller medication , eg , LTRA and/or theophylline Lowdose ICS/LABA fix combination therapy ( eg , low regular maintenance dose approve local country meet criterion ) Morning prebronchodilator ( preBD ) FEV1 &gt; 50 % ≤ 90 % predict Visit 2 . Clinically important pulmonary disease asthma ( eg , active lung infection , COPD , bronchiectasis , pulmonary fibrosis , cystic fibrosis , hypoventilation syndrome associate obesity , lung cancer , alpha 1 antitrypsin deficiency , primary ciliary dyskinesia ) ever diagnose pulmonary systemic disease , asthma , associate elevated peripheral eosinophil count ( eg , allergic bronchopulmonary aspergillosis/mycosis , ChurgStrauss syndrome , hypereosinophilic syndrome ) . Any disorder , include , limited , cardiovascular , gastrointestinal , hepatic , renal , neurological , musculoskeletal , infectious , endocrine , metabolic , hematological , psychiatric , major physical impairment stable opinion Investigator could : Affect safety patient throughout study nfluence finding study interpretation , Impede patient 's ability complete entire duration study . Known history allergy reaction investigational product formulation . History anaphylaxis biologic therapy . History GuillainBarré syndrome . A helminth parasitic infection diagnose within 24 week prior date informed consent obtain treat , fail respond standard care therapy . Acute upper low respiratory infection require antibiotic antiviral medication within 30 day prior date informed consent obtain screening/runin period . Any clinically significant abnormal finding physical examination , vital sign , hematology , clinical chemistry , urinalysis screening period , opinion Investigator , may put patient risk his/her participation study , may influence result study , patient 's ability complete entire duration study . Positive hepatitis B surface antigen , hepatitis C virus antibody serology , positive medical history hepatitis B C. Patients history hepatitis B vaccination without history hepatitis B allow enroll . A history know immunodeficiency disorder include positive human immunodeficiency virus ( HIV ) test . History cancer : Patients basal cell carcinoma , localize squamous cell carcinoma skin situ carcinoma cervix eligible provide patient remission curative therapy complete least 12 month prior date informed consent obtain . Patients malignancy eligible provide patient remission curative therapy complete least 5 year prior date informed consent obtain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Asthma , Bronchial Diseases , Respiratory Tract Diseases , Lung Diseases , Obstructive Lung Diseases ,</keyword>
</DOC>